14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $21.75 $29.07 Wednesday, 24th Apr 2024 ARWR stock ended at $23.29. This is 2.06% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 3.71% from a day low at $22.89 to a day high of $23.74.
90 days $21.75 $36.72
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
Feb 12, 2024 $32.56 $33.02 $31.47 $32.26 1 148 189
Feb 09, 2024 $30.93 $32.68 $30.62 $32.56 1 452 679
Feb 08, 2024 $31.93 $32.57 $30.77 $30.85 1 733 027
Feb 07, 2024 $31.75 $31.92 $29.50 $31.65 3 217 926
Feb 06, 2024 $31.93 $33.28 $31.55 $33.20 1 052 109
Feb 05, 2024 $31.23 $32.47 $30.54 $32.02 948 624
Feb 02, 2024 $31.52 $32.16 $30.65 $31.96 855 622
Feb 01, 2024 $32.25 $32.37 $31.32 $32.19 836 214
Jan 31, 2024 $32.91 $33.36 $31.79 $32.10 837 959
Jan 30, 2024 $34.19 $34.39 $32.95 $33.01 594 348
Jan 29, 2024 $32.62 $34.46 $32.00 $34.40 740 010
Jan 26, 2024 $33.67 $33.77 $32.56 $32.75 519 658
Jan 25, 2024 $33.00 $33.87 $32.86 $33.42 659 955
Jan 24, 2024 $34.58 $34.95 $32.78 $32.81 811 830
Jan 23, 2024 $33.89 $34.50 $33.42 $34.29 1 210 069
Jan 22, 2024 $33.83 $33.91 $32.58 $33.19 1 371 871
Jan 19, 2024 $33.32 $34.15 $32.90 $33.75 996 047
Jan 18, 2024 $34.39 $34.39 $32.71 $33.16 1 478 395
Jan 17, 2024 $34.40 $34.65 $33.48 $34.06 1 073 642
Jan 16, 2024 $36.03 $36.03 $34.32 $35.09 1 364 363
Jan 12, 2024 $37.62 $37.62 $35.56 $36.43 1 481 697
Jan 11, 2024 $39.22 $39.54 $37.36 $37.50 2 002 746
Jan 10, 2024 $38.24 $39.83 $37.71 $39.45 1 815 122
Jan 09, 2024 $38.91 $39.65 $37.26 $38.07 1 929 802
Jan 08, 2024 $35.10 $39.53 $34.37 $39.48 5 163 886
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT